Current Perspective on Residual Knowledge Gaps in the Assessment of Transporter-Mediated Drug Interactions
Published 2022. This article is a U.S. Government work and is in the public domain in the USA..
Assessment of transporter-mediated drug-drug interaction (DDI) is integral to drug development. A risk-based approach leveraging in vitro, in vivo, and in silico information is used to evaluate the DDI liability of drugs and inform the instructions of use. While tremendous advances have been made in recent decades, there are knowledge gaps warranting further research. Herein, we focus on select areas to advance assessment of DDI potential for drugs as substrates, inhibitors, or inducers of certain transporters.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
Clinical pharmacology and therapeutics - 112(2022), 3 vom: 20. Sept., Seite 450-452 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Xinning [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytochrome P-450 Enzyme Inducers |
|---|
| Anmerkungen: |
Date Completed 23.08.2022 Date Revised 13.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cpt.2671 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342440101 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342440101 | ||
| 003 | DE-627 | ||
| 005 | 20231226014122.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cpt.2671 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1141.xml |
| 035 | |a (DE-627)NLM342440101 | ||
| 035 | |a (NLM)35722741 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Xinning |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current Perspective on Residual Knowledge Gaps in the Assessment of Transporter-Mediated Drug Interactions |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.08.2022 | ||
| 500 | |a Date Revised 13.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published 2022. This article is a U.S. Government work and is in the public domain in the USA. | ||
| 520 | |a Assessment of transporter-mediated drug-drug interaction (DDI) is integral to drug development. A risk-based approach leveraging in vitro, in vivo, and in silico information is used to evaluate the DDI liability of drugs and inform the instructions of use. While tremendous advances have been made in recent decades, there are knowledge gaps warranting further research. Herein, we focus on select areas to advance assessment of DDI potential for drugs as substrates, inhibitors, or inducers of certain transporters | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cytochrome P-450 Enzyme Inducers |2 NLM | |
| 650 | 7 | |a Membrane Transport Proteins |2 NLM | |
| 700 | 1 | |a Reynolds, Kellie |e verfasserin |4 aut | |
| 700 | 1 | |a Madabushi, Rajanikanth |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Shiew-Mei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical pharmacology and therapeutics |d 1960 |g 112(2022), 3 vom: 20. Sept., Seite 450-452 |w (DE-627)NLM000015318 |x 1532-6535 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2022 |g number:3 |g day:20 |g month:09 |g pages:450-452 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cpt.2671 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2022 |e 3 |b 20 |c 09 |h 450-452 | ||